Richard Scranton is CSO at Pacira Pharmaceuticals, Inc. (PCRX). They have made 5 open-market trades across 1 company since 2018, most recently 2019-11-08.
CIK 0001709330
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 35,509 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2019-11-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL | 2019-11-08 | 2019-11-12 | $45.00 | $875K | +4.0% | +7.0% | +16.9% |
| PCRX | SELL | 2019-06-04 | 2019-06-06 | $42.98 | $600K | +3.1% | +1.9% | -13.9% |
| PCRX | SELL | 2019-06-03 | 2019-06-05 | $43.21 | $670K | -1.7% | -0.6% | -16.4% |
| PCRX | SELL | 2019-06-03 | 2019-06-05 | $43.21 | $670K | -1.7% | -0.6% | -16.4% |
| PCRX | SELL | 2018-06-04 | 2018-06-06 | $33.02 | $45K | -1.3% | -9.8% | +23.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.